We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Your Password has changed! Please login again
Cart
Outdated Browser Detected
Our website has detected that you are using an outdated browser that will prevent you from accessing certain features.
Please use one of the below recommended browsers to improve your browsing experience
Every pharmaceutical company wants to maximize speed to market for a new drug product. One way to enable this is with a platform approach for the package and delivery systems – in other words, to use the same vial containment system and/or syringe system for multiple drug products. To use this approach effectively, component and system performance data is needed. West, through the Integrated Solutions platform, is ideally positioned to provide this data.
Our Integrated Solutions program brings together West’s primary packaging, device, analytical, regulatory and contract manufacturing expertise in a single-source solution. West can help you Simplify the Journey™ at any stage of drug development. Learn more by visiting our Integrated Solutions Program page or contact a technical representative today for additional support and guidance.
Container closure integrity (CCI) is a fundamental requirement of every sterile drug package. Recently, the United States Pharmacopeia Convention (USP) published a guidance in this area that, among other key topics, addresses test methods in detail: Chapter <1207> Package Integrity Evaluation – Sterile Products. However, proper test method is only one aspect of achieving good CCI.
<p>On March 18, 2014, West CEO Don Morel was the keynote speaker for the Beacon of Hope dinner held to celebrate the United Way of the Kearney (Nebraska) Area’s 50th anniversary. More than 200 attendees were on hand to help celebrate, and to hear stories of West’ philanthropy, which included a $25,000 donation from West to help the United Way reach its 2014 campaign goal.</p>
Industry meetings continue to reinforce the changing landscape of the drug pipeline and the influence of biologic drug products in driving this change. At the recent DCAT Week, hosted by the Drug, Chemical and Associated Technologies Association, Josef Bossart, of PharmaCircle, provided an excellent overview of historic trends and current forecasts.
Many of the top-selling biologic drug products will soon come off-patent. As a result, according to IMS, the biosimilar market is expected to reach between US$1.9-2.6 billion by 2015.
<span style="color: #333333;">Earlier this month, <a href="/zh-cn/services/contract-manufacturing">West's contract manufacturing team</a>—formerly known as <span style="color: #000000;">The Tech Group</span>, officially received its Engineering and Production Technology Leadership award at the Frost & Sullivan Manufacturing Leadership Awards Gala in Carlsbad, California. Winners in this category were honored for embracing new design and production approaches to drive game-changing process improvements. </span>